Endocrine therapy for breast cancer prevention in high-risk women: Clinical and economic considerations

Amy G. Groom, Tallal Younis

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


The global burden of breast cancer highlights the need for primary prevention strategies that demonstrate both favorable clinical benefit/risk profile and good value for money. Endocrine therapy with selective estrogen-receptor modulators (SERMs) or aromatase inhibitors (AIs) has been associated with a favorable clinical benefit/risk profile in the prevention of breast cancer in women at high risk of developing the disease. The available endocrine therapy strategies differ in terms of their relative reductions of breast cancer risk, potential side effects, and upfront drug acquisition costs, among others. This review highlights the clinical trials of SERMs and AIs for the primary prevention of breast cancer, and the cost-effectiveness/cost-utility studies that have examined their "value for money" in various health care jurisdictions.

Original languageEnglish
Pages (from-to)245-255
Number of pages11
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number2
Publication statusPublished - Mar 3 2016
Externally publishedYes


  • aromatase inhibitors
  • breast cancer prevention
  • Chemoprevention
  • cost-utility
  • costeffectiveness
  • endocrine therapy
  • selective estrogen-receptor modulators

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)


Dive into the research topics of 'Endocrine therapy for breast cancer prevention in high-risk women: Clinical and economic considerations'. Together they form a unique fingerprint.

Cite this